By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1111 Main Street
Suite 660
Vancouver  Washington  98660  U.S.A.
Phone: 360-980-8524 Fax: 360-980-8549



Company News
CytoDyn (CYDY) Provides Further Update On PRO 140 Pivotal Combination Therapy Trial In Patients With HIV 9/6/2017 8:19:46 AM
CytoDyn (CYDY) Provides Update On PRO 140 Pivotal Combination Therapy Trial In Patients With HIV 8/21/2017 8:12:58 AM
CytoDyn (CYDY) Provides Update On Enrollment In Its Pivotal Phase Ib/III HIV Combination Trial 8/9/2017 12:09:50 PM
CytoDyn (CYDY) To Present An Update On Its PRO 140 Pivotal Phase IIb/III Study In Treatment-Experienced HIV-1 Patients At ASM Microbe 2017 6/1/2017 8:21:21 AM
CytoDyn (CYDY) Treats First Patient With PRO 140 In Phase II Trial For Graft Versus Host Disease 5/17/2017 8:14:12 AM
Potential For CytoDyn (CYDY)’s PRO 140 For Treating HIV Patients Deemed Too Broad For Orphan Drug Designation By The FDA 4/17/2017 8:01:28 AM
CytoDyn (CYDY) Appoints Scott A. Kelly, M.D. To Its Board Of Directors 4/11/2017 12:08:38 PM
Data Presented At CROI Show CytoDyn (CYDY)’s Pro 140 As A Single Agent Provided Maximal Virologic Suppression In HIV Patients For Nearly Two Years 2/16/2017 8:01:10 AM
CMC Biologics Enters Into Manufacturing Agreement With CytoDyn (CYDY) 2/15/2017 8:33:22 AM
Two-Year Update From CytoDyn (CYDY)’s PRO 140 Monotherapy Study In HIV To Be Featured In Two Events At CROI 2017 2/14/2017 10:58:06 AM